VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2015

Feb 20, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2015-02-18

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-02-18	Common Stock	M	1300	$17.16	Acquired	340195	Direct
2015-02-18	Common Stock	M	10400	$35.64	Acquired	350595	Direct
2015-02-18	Common Stock	S	7100	$112.87	Disposed	343495	Direct
2015-02-18	Common Stock	S	4600	$113.30	Disposed	338895	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-02-18	Stock Option (right to buy)	$17.16	M	1300	Disposed	2015-07-19	Common Stock (1300)	Direct
2015-02-18	Stock Option (right to buy)	$35.64	M	10400	Disposed	2016-02-01	Common Stock (10400)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	172589	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $112.87 (range $112.13 to $113.12).

F3: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $113.30 (range $113.13 to $113.52).

F5: Common stock held in grantor retained annuity trusts.

F6: Fully vested.